Novel strategies targeting residual risk: the promise of PCSK9 inhibiting therapies.

ESC Premium Access

Novel strategies targeting residual risk: the promise of PCSK9 inhibiting therapies.

Session: How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation

Topic: Inflammation and microcirculation

Speaker: Professor E. Stroes (Amsterdam, NL)

Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by unrestricted educational grants from Novartis and Amgen

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor Erik Stroes

Academic Medical Centre, Amsterdam (Netherlands (The))

39 presentations

0 follower

4 more presentations in this session

Introduction - The post ACS patient and residual risk.

Speaker: Professor P. Libby (Boston, US)

Access

Inflammation as potential target for therapy to target residual risk post ACS.

Speaker: Doctor P. Ridker (Boston, US)

Access

Beyond statins: the role of ezetimibe in targeting residual risk.

Speaker: Professor C. Packard (Glasgow, GB)

Access

Discussion - How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation.

Speaker: Professor P. Libby (Boston, US) Professor J. Deanfield (London, GB)

Access

Access the full session

How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation

Speakers: Professor E. Stroes, Professor P. Libby, Doctor P. Ridker, Professor C. Packard, Professor P. Libby...

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources